New safety labeling changes for fluoroquinolone antibiotics, require these medications to carry stronger warnings about potential mental health side effects and the risk of serious blood sugar disturbances. The US Food and Drug Administration (FDA) announced measures to improve labeling consistency...
Read More... Jul 14, 2018Bronchitis
Bronchitis often develops following a case of the common cold or the flu. The bronchial tubes carry air to the lungs, but these can become inflamed and infected. Symptoms of bronchitis include a hard-to-shift cough and large amounts of mucus forming.
Acute bronchitis is the most common form and it usually lasts for a few weeks. Fortunately, patients rarely experience further problems once it has cleared. however, chronic bronchitis is a recurring problem and it can be very difficult to clear up. Chronic bronchitis is one of the conditions that makes up chronic obstructive pulmonary disease (COPD).
Bronchitis is usually treated with rest, plenty of fluid intake and the avoidance of irritants such as smoke and fumes. Patients with chronic or severe cases may also be prescribed medication by their physician.
Antibiotics, such as fluoroquinolone antibiotics and penicillinase-sensitive penicillin antibiotics are among the most common medications prescribed to patients with bronchitis. These include amoxicillin, Cipro (ciprofloxacin) and Levaquin (levofloxacin).
Drugs Used To Treat Bronchitis:
Drugs related to Bronchitis:
Blog Posts Related to Bronchitis:
GlaxoSmithKline’s once-daily triple therapy, the Trelegy Ellipta (fluticasone furoate, umeclidinium, vilanterol), is superior to dual combination therapies in reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD) with a history of exacerbations, new research...
Read More... Apr 23, 2018The US Food and Drug Administration (FDA) has approved Sunovion’s Lonhala Magnair (glycopyrrolate), making it the first nebulized long-acting muscarinic antagonist (LAMA) treatment in the United States for patients with chronic obstructive pulmonary disease (COPD). It is expected to appear in...
Read More... Dec 08, 2017The US Food and Drug Administration (FDA) has approved a new once-daily single inhaler triple therapy for treatment of certain adults with chronic obstructive pulmonary disease (COPD). Trelegy Ellipta (furoate, umeclidinium, vilanterol) is indicated for patients on a fixed-dose combination...
Read More... Nov 15, 2017Login or Register to Share!
For every friend or family member you refer you will earn 100 Reward Points on their first prescription purchase! Plus you earn Reward Points on every prescription purchase they make with their ModRN Health card.
You may share without logging in or registering, but please note you will not receive any reward points.